Altimmune (ALT) EBITDA Margin (2010 - 2025)

Altimmune (ALT) has 16 years of EBITDA Margin data on file, last reported at 104884.62% in Q4 2025.

• EBITDA Margin for Q4 2025 came in at 104884.62%, up 36127538.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 214751.22% (up 26038878.0% YoY), and the FY2025 annual result was 214751.22%, up 26038878.0% from the prior year.
• EBITDA Margin improved to 104884.62% in Q4 2025 per ALT's latest filing, from 379820.0% in the prior quarter.
• Over five years, EBITDA Margin peaked at 728.99% in Q4 2021 and troughed at 1182950.0% in Q3 2022.
• A 5-year average of 264861.84% and a median of 178861.06% in 2025 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin sank 116173987 bps in 2022, then surged 117725525 bps in 2023.
• A 5-year view of EBITDA Margin shows it stood at 728.99% in 2021, then plunged by 11288 bps to 83015.38% in 2022, then retreated by 3 bps to 85191.89% in 2023, then tumbled by 447 bps to 466160.0% in 2024, then surged by 78 bps to 104884.62% in 2025.
• Business Quant data shows ALT's EBITDA Margin at 104884.62% in Q4 2025, 379820.0% in Q3 2025, and 443640.0% in Q2 2025.